Pharmaceutical companies based in South Korea and overseas are having difficulties developing new drugs for multiple sclerosis. Sanofi failed to demonstrate the drug's efficacy in some parts of clinical trials, and Merck's Phase 3 clinical trial did not meet primary endpoints.

However, Sanofi announced that it will attempt to receive approval from the U.S. Food and Drug Administration (FDA) since the company acquired results confirming the efficacy in some parts of the clinical trial. In South Korea, D&D Pharmatech and AprilBIO jump into drug development.

Sanofi fails to meet the primary endpoints in some of the Phase 3 clinical trials